P1576: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF V114 PNEUMOCOCCAL VACCINE IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS (PNEU-STEM)
M. Wilck,
O. Cornely,
P. Ljungman,
C. Cordonnier,
J. Diego Velez,
R. Dagan,
P. Richmond,
Q. Chen,
C. Daus,
K. Geddie,
T. Sterling,
T. Shekar,
L. Musey,
U. Buchwald
Affiliations
M. Wilck
1 Merck & Co., Inc., Kenilworth, United States of America
O. Cornely
2 University Clinic Cologne, Cologne, Germany
P. Ljungman
3 Karolinska University Hospital, Stockholm, Sweden
C. Cordonnier
4 Henri Mondor Hospital, Creteil, France
J. Diego Velez
5 Fundacion Valle del Lili, Cali, Colombia
R. Dagan
6 Ben-Gurion University, Beer-Sheva, Israel
P. Richmond
7 University of Western Australia, Perth, Australia
Q. Chen
1 Merck & Co., Inc., Kenilworth, United States of America
C. Daus
1 Merck & Co., Inc., Kenilworth, United States of America
K. Geddie
1 Merck & Co., Inc., Kenilworth, United States of America
T. Sterling
1 Merck & Co., Inc., Kenilworth, United States of America
T. Shekar
1 Merck & Co., Inc., Kenilworth, United States of America
L. Musey
1 Merck & Co., Inc., Kenilworth, United States of America
U. Buchwald
1 Merck & Co., Inc., Kenilworth, United States of America
